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to inhibit gram positive stainsBacillus subtilis andStaphylococcus aureus, gram negative stainsEsch-
erichia coli and Pseudomonas aeruginosa, and fungi Candida albicans were studied. Carbonyl piper-
azines attached at C-3 position of pyridoquinolone exhibited good antibacterial activity when
compared to standard drugs ciproﬂoxacin and gatiﬂoxacin. Indeed carbonyl piperazine derivatives
24–32 when attached at C-3 position of pyridoquinolone increased the activity of their parent com-
pound 6 than that of carbonyl ureas 8–23 exhibited lower antibacterial activity compared to car-
bonyl piperazine derivatives 24–32.
ª 2010 King Saud University. Production and hosting by Elsevier B.V.Open access under CC BY-NC-ND license.1. Introduction
Quinolones are known to inhibit DNA synthesis by promoting
cleavage of bacterial DNA gyrase and type-IV topoisomerase,
resulting in rapid bacterial death (Hooper and Wolfson, 1989;
Hooper, 1995, 1998; Hardman et al., 2002). Quinolones with261 2264746; fax: +91 0262
t.in (N.B. Patel), drjaymin@
mail.com (S.H. Modi).
y. Production and hosting by
Saud University.
lsevier
ND license.substituents at C-6 position, albeit less activity than ﬂuorine,
are essential for high activity as evidenced by its enhanced
gyrase inhibition and cell penetration (Bhanot et al., 2001;
Daniel and Prabhavathi, 1989). A number of substituents for
ﬂuorine replacement have been introduced into that position.
Garenoxacin (Fig. 1) showed greater potency than the new-
er ﬂuoroquinolone (Figs. 2 and 3) and moxiﬂoxacin (Fig. 4)
against both sensitive and resistant gram positive organisms.
Thus casting doubt on the validity of necessity of C-6 ﬂuorine
(Emami et al., 2005). Several efforts to further modify non-
ﬂuoroquinolone and their biological activities were also inves-
tigated (Ctoen-Chackal et al., 2004; Chevalier et al., 2001; Lee
et al., 1994). In course of our studies on carbonyl derivatives of
pyridiquinolone (Patel and Modi, 2006; Patel and Bhagat,
2006; Patel et al., 2007), we explored synthetic process to
non ﬂuoro 1-methyl-6-hydroxy-4-oxo-pyrido[2,3-h]quinoline
ring system to prepare carbonyl derivatives containing aryl
ureas and piperazines to examine their potential antibacte-
rial activities. We report here the synthesis of new ureido
carbonyl pyridoquinolones 8–23 and piperazinyl carbonyl
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168 N.B. Patel et al.pyridoquinolones 24–33 and their in vitro antibacterial and
antifungal screening results are presented.
2. Experimental
All chemical were of analytical grade and used directly. Melt-
ing points were determined on PMP-DM scientiﬁc melting
point apparatus and are uncorrected. Thin layer chromatogra-
phy (TLC) was done on Merck silica gel 60 F254 plates using
toluene:ethylacetate (8:2) as a mobile phase and spots were
visualized under UV light. IR spectra were recorded on a Per-
kin–Elmer RX 1 FTIR spectrophotometer, using potassium
bromide pellets and the frequencies are expressed in cm1.
The 1H NMR and 13C NMR spectra were recorded with a
Bruker Avance II 400 NMR spectrometer, using tetramethyl-
silane as the internal reference in dimethylsulphoxide
DMSO-d6. The chemical shifts are reported in parts per mil-
lion (d ppm). Elemental analyses were performed on a Heraeus
Carlo Erba 1180 CHN analyzer.2.1. Synthesis of 5-amino-8-hydroxyquinoline (2)
Nitroxoline 1 (2 g, 0.0106 mol) was added gradually to a well-
stirred solution of stannous chloride dihydrate (9.6 g) in con-
centrated HCl (30 ml), cooled to below 10 C in an ice bath.
After addition was completed, solution was heated on a water
bath for 3–5 h. Then cooled it to room temperature, precipitate
of amine hydrochloride (mp 278 C) was obtained, ﬁltered and
dissolved in water (50 ml), adjusted pH 7–8 carefully with di-
lute sodium bicarbonate solution. Red precipitate was col-
lected and puriﬁed by silica gel column chromatography
using ethylacetate and petroleum ether (1:2) to give 2 (1.36 g,
yield: 80%, mp 222–225 C), and was used in the next step.
FT-IR (KBr) 3518, 3392 (NH2), 3447 (OH) cm
1; 1H NMR
(300 MHz, DMSO-d6) d 10.82 (s, 1H, OH), 8.94–6.78 (m,
5H, Ar-H), 5.05 (bs, 2H, NH2);
13C NMR (75.47 MHz,
DMSO-d6) d 149.7, 145.2, 139.3, 134.2, 126.4, 121.8, 115.3,
114.8, 114.2; Anal. Calcd for C9H8N2O (%): C, 67.49; N,
17.49. Found: C, 67.35; N, 17.38.
2.2. Synthesis of diethyl 2-[(8-hydroxyquinolin-5-yl-amino)-
methylene]malonate (3)
A mixture of 8-hydroxy-5-amino quinoline 2 (1.2 g,
0.0074 mol) and diethyl ethoxy methylene malonate EMME
(1.6 ml, 0.0074 mol) was heated at 110 C for 5–6 h to yield
yellow solid. The product was recrystalized from ethanol.
Yield: 74%, mp 128–132 C; FT-IR (KBr) 3465–3230 (NH
and OH), 3173, 3074 (CH‚CH), 1717 (C‚O) cm1; 1H
NMR (300 MHz, DMSO-d6) d 11.76 (d, 1H, J= 12.81 Hz,
NH), 10.84 (bs, 1H, OH), 9.06–7.38 (m, 5H, Ar-H), 8.57 (d,
1H, J= 12.81 Hz, N–CH), 4.43–4.21 (m, 4H, 2CH2), 1.47–
1.28 (m, 6H, 2CH3);
13C NMR (75.47 MHz, DMSO-d6) d
171.5, 149.2, 146.1, 141.4, 133.8, 132.1, 127.4, 126.3, 123.1,
115.8, 115.2, 114.6, 60.5, 14.2; Anal. Calcd for C17H18N2O5
(%): C, 61.81; N, 8.48. Found: C, 61.73; N, 8.41.
2.3. Synthesis of ethyl 6-hydroxy-4-oxo-pyrido[2,3-h]quinoline-
3-carboxylate (4)
Compound 3 (1 g, 0.003 mol) was suspended in diphenyl ether
(10 ml) and heated for 2–4 h at 200 C. Then the reaction mix-
ture was cooled to room temperature and the resulting solid
was ﬁltered and washed with pet ether (give boiling range)
and recrystalized from DMF to give 750 mg of 4 as pure prod-
uct. Yield: 80%, mp 245–250 C; FT-IR (KBr) 3470–3240 (NH
and OH), 3080, 2985 (C–H), 1707 (C‚O) cm1; 1H NMR
(300MHz, DMSO-d6) d 12.76 (bs, 1H, NH), 10.83 (bs, 1H, OH),
9.43–8.48 (m, 3H, pyrido ring), 8.77 (s, 1H, H-2), 7.87 (q,
1H, J= 4.68 Hz, H-5), 4.36 (q, 2H, J= 7.14 Hz, CH2), 1.32
(t, 3H, J= 7.14 Hz, CH3);
13C NMR (75.47 MHz, DMSO-d6)
d 175.1, 170.7, 149.4, 145.2, 140.7, 139.9, 138.5, 138.2, 125.6,
122.4, 117.2, 116.3, 115.5, 58.3, 17.2; Anal. Calcd for
C15H12N2O4 (%): C, 63.38; N, 9.85. Found: C, 63.27; N, 9.78.
2.4. Synthesis of ethyl-1-methyl-6-hydroxy-4-oxo-pyrido[2,3-
h]quinoline-3-carboxylate (5)
The mixture of compound 4 (0.65 g, 0.0023 mol), methyl io-
dide (1.7 g, 0.0109 mol) and anhydrous K2CO3 (0.95 g,
0.0069 mol) in DMF (20 ml) was heated at 60 C for 3–6 h.
Synthesis and antimicrobial activity of carbonyl pyridoquinolones 169After completion of the reaction, DMF was evaporated under
reduced pressure and the residue was dissolved in water and
extracted with CHCl3, dried with anhydrous MgSO4 and con-
centrated to dryness under reduced pressure. The crude prod-
uct was puriﬁed by silica gel column chromatography using
ethyl acetate and petroleum ether (4:1) as an eluent. Yield:
70%, mp 124–127 C; FT-IR (KBr) 3485 (OH), 3020, 2920
(C–H), 2790 (N–CH3), 1720 (C‚O) cm
1; 1H NMR
(300 MHz, DMSO-d6) d 10.95 (bs, 1H, OH), 9.48–8.52 (m,
3H, pyrido ring), 9.17 (s, 1H, H-2), 7.91 (q, 1H,
J= 4.71 Hz, H-5), 4.37 (q, 2H, J= 7.14 Hz, CH2), 4.08 (s,
3H, CH3), 1.35 (t, 3H, J= 7.14 Hz, CH3);
13C NMR
(75.47 MHz, DMSO-d6) d 174.5, 167.6, 149.8, 148.2, 140.3,
138.1, 137.5, 135.8, 132.4, 124.5, 124.5, 121.2, 110.3, 58.8,
18.4, 44.1; Anal. Calcd for C16H14N2O4 (%): C, 64.42; N,
9.39. Found: C, 64.29; N, 9.32.
2.5. Synthesis of N-methyl-6-hydroxy-4-oxo-pyrido
[2,3-h]quinoline-3-carboxylic acid (6)
Compound 5 (1 g, 0.0032 mol) was dissolved in 15% HCl
(50 ml) solution and stirred at room temperature for 1–3 h.
The reaction mix was adjusted to pH 7–8 with dilute ammonia
solution to give off white product. The product 6 was recrystal-
ized from DMF. Yield: 30%, mp 280–283 C; FT-IR (KBr)
3465 (OH), 3100–2620 (COOH), 1715 (C‚O) cm1; 1H
NMR (300 MHz, DMSO-d6) d 14.97 (bs, 1H, COOH), 11.13
(bs, 1H, OH), 9.46–8.49 (m, 3H, pyrido ring), 9.26 (s, 1H,
H-2), 7.96 (q, 1H, J= 4.65 Hz, H-5), 4.12 (s, 3H, CH3);
13C
NMR (75.47 MHz, DMSO-d6) d 177.2, 168.4, 148.6, 147.2,
142.3, 140.5, 138.9, 134.7, 131.2, 128.1, 125.5, 120.4, 114.2,
44.6; Anal. Calcd for C14H10N2O4 (%): C, 62.22; N, 10.37.
Found: C, 62.14; N, 10.28.
2.6. General procedure for the synthesis of ureido carbonyl
pyridoquinolones (8–23)
Compound 6 (1.3 g, 0.005 mol) was dissolved in dry benzene
(15 ml), cooled to 0–5 C in ice-bath and thionyl chloride
(2 ml) was added drop by drop with stirring; the reaction mix-
ture was protected from humidity with calcium chloride guard
tube and heated for 3–5 h at 60 C on water bath and the ex-
cess of thionyl chloride was removed by distillation with ben-
zene to give pure acid chloride 7 in good yield; in this
anhydrous methanol (25 ml), pyridine (0.5 ml) and substituted
aryl ureas (0.005 mol) were added and reﬂuxed for 5–8 h. The
reaction mass was poured into acidic ice-water (50 ml 0.5%
HCl). The product was precipitated, ﬁltered and recrystalized
from ethanol. Similarly other ﬁfteen derivatives 9–23 have
been prepared by the same method.
2.6.1. 1-Methyl-6-hydroxy-3-(N3-phenylureido)carbonyl-4-
oxo-pyrido[2,3-h]quinoline (8)
White solid, yield: 76%, mp 222–226 C; FT-IR (KBr) 3405
(OH), 2815 (C–H), 1707 (C‚O), 1670 (Amide-I), 1540
(Amide-II), 1240 (Amide-III) cm1; 1H NMR (300 MHz,
DMSO-d6) d 11.43 (bs, 1H, OH), 10.48 (bs, 1H, NH), 9.74
(bs, 1H, NH), 9.34–8.23 (m, 3H, pyrido ring), 9.12 (s, 1H,
H-2), 8.16 (q, 1H, J= 4.71 Hz, H-5), 7.23–6.88 (m, 5H, Ar-
H), 4.14 (s, 3H, CH3);
13C NMR (75.47 MHz, DMSO-d6) d
181, 174.2, 164.4, 154, 156.1, 143.2, 138.0, 137, 129, 128.2,127.2, 126.1, 124.3, 123.1, 121, 117.3, 111, 108.1, 34.9; MS
(IS) m/z [MH+] 389.4; Anal. Calcd for C21H16N4O4 (%): C,
64.94; N, 14.43. Found: C, 64.61; N, 14.66.
2.6.2. 1-Methyl-6-hydroxy-3-(N3-2-chlorophenylureido)carbonyl-
4-oxo-pyrido[2,3-h] quinoline (9)
White solid, yield: 72%, mp 216–220 C; FT-IR (KBr) 3443
(OH), 2800 (C–H), 1717 (C‚O), 1664 (Amide-I), 1549
(Amide-II), 1248 (Amide-III) cm1; 1H NMR (300 MHz,
DMSO-d6) d 10.98 (bs, 1H, OH), 10.76 (bs, 1H, NH), 9.82
(bs, 1H, NH), 9.41–8.29 (m, 3H, pyrido ring), 9.14 (s, 1H,
H-2), 8.11 (q, 1H, J= 4.65 Hz, H-5), 7.95–6.93 (m, 4H,
Ar-H), 4.19 (s, 3H, CH3);
13C NMR (75.47 MHz, DMSO-
d6) d 185, 172.2, 163.2, 156.5, 151, 147.2, 138.5, 138, 137,
136, 129, 127.6, 126.9, 125, 124, 123.4, 122, 118, 110, 108.5,
36.5; MS (IS) m/z [MH+] 423.8; Anal. Calcd for C21H15
ClN4O4 (%): C, 59.65; N, 13.25. Found: C, 59.61; N 13.56.
2.6.3. 1-Methyl-6-hydroxy-3-(N3-3-chlorophenylureido)carbonyl-
4-oxo-pyrido[2,3-h] quinoline (10)
White solid, yield: 64%, mp 256–260 C; FT-IR (KBr) 3437
(OH), 2788 (C–H), 1723 (C‚O), 1667 (Amide-I), 1553
(Amide-II), 1242 (Amide-III) cm1; 1H NMR (300 MHz,
DMSO-d6) d 11.07 (bs, 1H, OH), 10.81 (bs, 1H, NH), 9.68
(bs, 1H, NH), 9.49–8.32 (m, 3H, pyrido ring), 9.15 (s, 1H, H-2),
8.06 (q, 1H, J= 4.68 Hz, H-5), 7.89–6.84 (m, 4H, Ar-H), 4.13
(s, 3H, CH3);
13C NMR (75.47 MHz, DMSO-d6) d 185.3, 172.1,
163.4, 156.8, 150.7, 147.5, 138.2, 138.1, 137.5, 135.6, 128.7,
127.8, 126.6, 125.2, 124.1, 123.2, 122.3, 118.2, 110.9, 108.2, 36.3;
MS (IS) m/z [MH+] 423.6; Anal. Calcd for C21H15ClN4O4 (%):
C, 59.65; N, 13.25. Found: C, 59.26; N, 13.11.
2.6.4. 1-Methyl-6-hydroxy-3-(N3-4-chlorophenylureido)carbonyl-
4-oxo-pyrido[2,3-h] quinoline (11)
White solid, yield: 76%, mp 239–243 C; FT-IR (KBr) 3452
(OH), 2795 (C–H), 1720 (C‚O), 1665 (Amide-I), 1548
(Amide-II), 1246 (Amide-III) cm1; 1H NMR (300 MHz,
DMSO-d6) d 11.27 (bs, 1H, OH), 10.93 (bs, 1H, NH), 9.79
(bs, 1H, NH), 9.44–8.36 (m, 3H, pyrido ring), 9.14 (s, 1H,
H-2), 8.17 (q, 1H, J= 4.65 Hz, H-5), 8.03–6.86 (m, 4H, Ar-
H), 4.21 (s, 3H, CH3);
13C NMR (75.47 MHz, DMSO-d6) d
185.2, 172.0, 163.3, 156.5, 150.6, 147.7, 138.5, 138.3, 137.4,
135.3, 128.9, 128.1, 126.8, 125.4, 124.2, 123.5, 122.1, 118.7,
110.6, 108.3, 36.4; MS (IS) m/z [MH+] 423.7; Anal. Calcd
for C21H15ClN4O4 (%): C, 59.65; N, 13.25. Found: C, 59.33;
N, 13.49.
2.6.5. 1-Methyl-6-hydroxy-3-(N3-2-methoxyphenylureido)
carbonyl-4-oxo-pyrido[2,3-h] quinoline (12)
White solid, yield: 66%, mp 252–256 C; FT-IR (KBr) 3450
(OH), 2805 (C–H), 1727 (C‚O), 1658 (Amide-I), 1553
(Amide-II), 1251 (Amide-II), 1238, 1042 (C–O–C) cm1; 1H
NMR (300 MHz, DMSO-d6) d 11.12 (s, 1H, OH), 10.86 (bs,
1H, NH), 9.81 (bs, 1H, NH), 9.58–8.33 (m, 3H, pyrido ring),
9.18 (bs, 1H, H-2), 8.11 (q, 1H, J= 4.71 Hz, H-5), 8.17–7.23
(m, 4H, Ar-H), 3.45 (s, 3H, OCH3), 4.14 (s, 3H, CH3);
13C
NMR (75.47 MHz, DMSO-d6) d 182.8, 173.3, 163.2, 157.7,
154.2, 151.1, 147.2, 139.5, 137.8, 136.4, 130.7, 122.2, 122.1,
121.3, 118.7, 114.2, 111.3, 108.5, 48.3, 37.1; MS (IS) m/z
[MH+] 420.3; Anal. Calcd for C22H18N4O5 (%): C, 63.15;
N, 13.39. Found: C, 63.40; N, 13.28.
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carbonyl-4-oxo-pyrido[2,3-h]quinoline (13)
White solid, yield: 78%, mp 259–262 C; FT-IR (KBr) 3455
(OH), 2800 (C–H), 1732 (C‚O), 1663 (Amide-I), 1552
(Amide-II), 1246 (Amide-II), 1232, 1034 (C–O–C) cm1; 1H
NMR (300 MHz, DMSO-d6) d 11.23 (bs, 1H, OH), 10.82
(bs, 1H, NH), 9.91 (bs, 1H, NH), 9.52–8.28 (m, 3H, pyrido
ring), 9.27 (s, 1H, H-2), 8.05 (q, 1H, J= 4.74 Hz, H-5),
8.14–7.22 (m, 4H, Ar-H), 3.32 (s, 3H, OCH3), 4.19 (s, 3H,
CH3);
13C NMR (75.47 MHz, DMSO-d6) d 183, 173.1, 162.7,
157.4, 154, 151.4, 146.8, 139.4, 137.4, 136.2, 131, 122.4, 122,
121.1, 118.4, 114, 111.2, 108.2, 48.2, 37.2; MS (IS) m/z
[MH+] 419.2; Anal. Calcd for C22H18N4O5 (%): C, 63.15;
N, 13.39. Found: C, 63.48; N, 13.25.
2.6.7. 1-Methyl-6-hydroxy-3-(N3-2-methylphenylureido)
carbonyl-4-oxo-pyrido[2,3-h] quinoline (14)
White solid, yield: 71%, mp 282–285 C; FT-IR (KBr) 3342
(OH), 2926, 2860 (CH3) 2793 (C–H), 1735 (C‚O), 1678
(Amide-I), 1566 (Amide-II), 1246 (Amide-III) cm1; 1H
NMR (300 MHz, DMSO-d6) d 11.02 (bs, 1H, OH), 10.83
(bs, 1H, NH), 9.92 (bs, 1H, NH), 9.42–8.24 (m, 3H, pyrido
ring), 9.13 (s, 1H, H-2), 8.19 (q, 1H, J= 4.65 Hz, H-5),
8.15–7.04 (m, 4H, Ar-H), 4.11 (s, 3H, CH3), 1.28 (s, 3H,
CH3);
13C NMR (75.47 MHz, DMSO-d6) d 184.6, 172.2,
163.4, 155.6, 150.2, 144.9, 138.5, 138.2, 137.4, 136.8, 136.1,
129.4, 128.2, 124.4, 119.2, 121.3, 120.1, 117.6, 110.5, 108.3,
37.2, 18.3; MS (IS) m/z [MH+] 403.5; Anal. Calcd for
C22H18N4O4 (%): C, 65.66; N, 13.92. Found: C, 65.40; N,
14.03.
2.6.8. 1-Methyl-6-hydroxy-3-(N3-3-methylphenylureido)
carbonyl-4-oxo-pyrido[2,3-h] quinoline (15)
White solid, yield: 68%, mp 276–279 C; FT-IR (KBr) 3341
(OH), 2930, 2864 (CH3) 2797 (C–H), 1728 (C‚O), 1675
(Amide-I), 1562 (Amide-II), 1252 (Amide-III) cm1; 1H
NMR (300 MHz, DMSO-d6) d 10.92 (bs, 1H, OH), 10.74
(bs, 1H, NH), 9.69 (bs, 1H, NH), 9.53–8.22 (m, 3H, pyrido
ring), 9.19 (s, 1H, H-2), 8.12 (q, 1H, J= 4.59 Hz, H-5),
8.16–7.14 (m, 4H, Ar-H), 4.05 (s, 3H, CH3), 1.37 (s, 3H,
CH3);
13C NMR (75.47 MHz, DMSO-d6) d 184.2, 172.6, 163,
155.3, 149.9, 145.2, 138.3, 138, 137, 136.9, 136.6, 129, 128,
124, 119, 121.4, 120.5, 117.8, 110.2, 108, 37, 18.5; MS (IS)
m/z [MH+] 403.3; Anal. Calcd for C22H18N4O4 (%): C,
65.66; N, 13.92. Found: C, 65.26; N, 13.85.
2.6.9. 1-Methyl-6-hydroxy-3-(N3-4-methylphenylureido)
carbonyl-4-oxo-pyrido[2,3-h] quinoline (16)
White solid, yield: 74%, mp > 290 C; FT-IR (KBr) 3345
(OH), 2932, 2867 (CH3) 2785 (C–H), 1723 (C‚O), 1678
(Amide-I), 1557 (Amide-II), 1256 (Amide-III) cm1; 1H
NMR (300 MHz, DMSO-d6) d 10.79 (bs, 1H, OH), 10.68
(bs, 1H, NH), 9.83 (bs, 1H, NH), 9.56–8.24 (m, 3H, pyrido
ring), 9.13 (s, 1H, H-2), 8.16 (q, 1H, J= 4.62 Hz, H-5),
8.13–7.15 (m, 4H, Ar-H), 4.18 (s, 3H, CH3), 1.45 (s, 3H,
CH3);
13C NMR (75.47 MHz, DMSO-d6) d 184.4, 172.2,
163.3, 155.1, 149.6, 145.6, 138.4, 138.2, 137.1, 136.6, 136.3,
128.8, 128.2, 124.4, 119.2, 121.7, 120.6, 117.7, 110.1, 108.3,
37.2, 18.3; MS (IS) m/z [MH+] 403.2; Anal. Calcd for
C22H18N4O4 (%): C, 65.66; N, 13.92. Found: C, 65.32; N,
13.80.2.6.10. 1-Methyl-6-hydroxy-3-(N3-2-nitrophenylureido)
carbonyl-4-oxo-pyrido[2,3-h] quinoline (17)
Yellow solid, yield: 76%, mp 231–234 C; FT-IR (KBr) 3415
(OH), 2782 (C–H), 1714 (C‚O), 1662 (Amide-I), 1553
(Amide-II), 1523 (N‚O), 1335 (N‚O), 1250 (Amide-III)
cm1; 1H NMR (300 MHz, DMSO-d6) d 11.25 (bs, 1H, OH),
10.74 (bs, 1H, NH), 9.86 (bs, 1H, NH), 9.58–8.41 (m, 3H, pyr-
ido ring), 9.32 (s, 1H, H-2), 7.94 (q, 1H, J= 4.59 Hz, H-5),
8.13–7.23 (m, 4H, Ar-H), 4.12 (s, 3H, CH3);
13C NMR
(75.47 MHz, DMSO-d6) d 182.3, 170.3, 161.2, 155, 150,
141.0, 145, 139, 137, 136.5, 135.7, 133.3, 129.8, 127, 124, 123,
122.6, 120, 113, 110.5, 36; MS (IS) m/z [MH+] 434; Anal.
Calcd for C21H15N5O6 (%): C, 58.20; N, 16.16. Found: C,
58.35; N, 16.28.
2.6.11. 1-Methyl-6-hydroxy-3-(N3-3-nitrophenylureido)
carbonyl-4-oxo-pyrido[2,3-h] quinoline (18)
Orange solid, yield: 65%, mp 252–256 C; FT-IR (KBr)
3423 (OH), 2787 (C–H), 1718 (C‚O), 1668 (Amide-I),
1557 (Amide-II), 1526, 1332 (NO2), 1242 (Amide-III) cm
1;
1H NMR (300 MHz, DMSO-d6) d 11.19 (bs, 1H, OH),
10.62 (bs, 1H, NH), 9.81 (bs, 1H, NH), 9.47–8.43 (m,
3H, pyrido ring), 9.23 (s, 1H, H-2), 7.83 (q, 1H,
J= 4.65 Hz, H-5), 8.22–7.29 (m, 4H, Ar-H), 4.19 (s, 3H,
CH3);
13C NMR (75.47 MHz, DMSO-d6) d 182.1, 170.4,
161.5, 155.2, 150.3, 141.1, 145.4, 138.9, 136.8, 136.7,
135.6, 133.5, 129.7, 127.2, 124.1, 123.5, 122.4, 120.2,
113.5, 110.8, 36.1; MS (IS) m/z [MH+] 434.4; Anal. Calcd
for C21H15N5O6 (%): C, 58.20; N, 16.16. Found: C,
58.49; N, 16.25.2.6.12. 1-Methyl-6-hydroxy-3-(N3-4-nitrophenylureido)
carbonyl-4-oxo-pyrido[2,3-h] quinoline (19)
Yellow solid, yield: 75%, mp 241–244 C; FT-IR (KBr) 3425
(OH), 2792 (C–H), 1722 (C‚O), 1670 (Amide-I), 1555
(Amide-II), 1530, 1336 (NO2), 1249 (Amide-III) cm
1; 1H
NMR (300 MHz, DMSO-d6) d 11.23 (bs, 1H, OH), 10.74
(bs, 1H, NH), 9.77 (bs, 1H, NH), 9.52–8.33 (m, 3H, pyrido
ring), 9.13 (s, 1H, H-2), 7.92 (q, 1H, J= 4.74 Hz, H-5),
8.28–7.39 (m, 4H, Ar-H), 4.27 (s, 3H, CH3);
13C NMR
(75.47 MHz, DMSO-d6) d 181.9, 170.6, 161.2, 155.8, 150.6,
141.2, 145.1, 138.6, 137.2, 136.5, 135.2, 133.1, 129.8, 127.6,
124.3, 123.9, 122.7, 120.4, 113.3, 110.7, 36.2; MS (IS) m/z
[MH+] 434.2; Anal. Calcd for C21H15N5O6 (%): C, 58.20;
N, 16.16. Found: C, 58.02; N, 16.00.2.6.13. 1-Methyl-6-hydroxy-3-(N3-2,5-dichlorophenylureido)
carbonyl-4-oxo-pyrido[2,3-h]quinoline (20)
Pale yellow solid, yield: 66%, mp > 300 C (d); FT-IR (KBr)
3425 (OH), 2802 (C–H), 1720 (C‚O), 1672 (Amide-I), 1562
(Amide-II), 1253 (Amide-III) cm1; 1H NMR (300 MHz,
DMSO-d6) d 11.29 (bs, 1H, OH), 10.98 (bs, 1H, NH), 10.06
(bs, 1H, NH), 9.54–8.35 (m, 3H, pyrido ring), 9.08 (s, 1H,
H-2), 8.04 (q, 1H, J= 4.71 Hz, H-5), 8.05–7.42 (m, 3H, Ar-
H), 4.13 (s, 3H, CH3);
13C NMR (75.47 MHz, DMSO-d6) d
184.1, 171.4, 162.6, 155.4, 151.2, 147.2, 146, 142, 138.3, 138,
137.2, 136.5, 136, 123.2, 127.6, 126.4, 121.6, 117.8, 109.2,
107.2, 37.1; MS (IS) m/z [MH+] 458; Anal. Calcd for
C21H14Cl2N4O4 (%): C, 55.16; N, 12.25. Found: C, 55.44; N,
12.03.
Synthesis and antimicrobial activity of carbonyl pyridoquinolones 1712.6.14. 1-Methyl-6-hydroxy-3-(N3-2-chloro-5-nitrophenyl-
ureido)carbonyl-4-oxo-pyrido[2,3-h]quinoline (21)
Light brown solid, yield: 72.5%, mp 272–276 C; FT-IR (KBr)
3345 (OH), 2798 (C–H), 1720 (C‚O), 1665 (Amide-I), 1553
(Amide-II), 1532, 1338 (NO2), 1252 (Amide-III) cm
1; 1H
NMR (300 MHz, DMSO-d6) d 11.12 (bs, 1H, OH), 10.83
(bs, 1H, NH), 9.89 (bs, 1H, NH), 9.65–8.36 (m, 3H, pyrido
ring), 9.28 (s, 1H, H-2), 7.93 (q, 1H, J= 4.77 Hz, H-5),
8.23–6.95 (m, 3H, Ar-H), 4.03 (s, 3H, CH3);
13C NMR
(75.47 MHz, DMSO-d6) d 182.5, 172.3, 163.5, 158.3, 152.4,
145.9, 145.2, 138.4, 138.2, 136.8, 136.2, 134.5, 134.1, 132.2,
122.8, 122.3, 120.4, 117.3, 110.7, 108.3, 36.5; MS (IS) m/z
[MH+] 468.1; Anal. Calcd for C21H14ClN5O6 (%): C, 53.92;
N, 14.97. Found: C, 54.06; N, 14.52.
2.6.15. 1-Methyl-6-hydroxy-3-(N3-2-nitro-5-chloropheny-
lureido)carbonyl-4-oxo-pyrido[2,3-h]quinoline (22)
Light brown solid, yield: 80%, mp 252–254 C; FT-IR (KBr)
3336 (OH), 2791 (C–H), 1717 (C‚O), 1670 (Amide-I), 1551
(Amide-II), 1529, 1334 (NO2), 1248 (Amide-III) cm
1; 1H
NMR (300 MHz, DMSO-d6) d 11.17 (bs, 1H, OH), 10.86
(bs, 1H, NH), 9.85 (bs, 1H, NH), 9.57–8.32 (m, 3H, pyrido
ring), 9.22 (s, 1H, H-2), 7.92 (q, 1H, J= 4.74 Hz, H-5),
8.11–7.03 (m, 3H, Ar-H), 3.94 (s, 3H, CH3);
13C NMR
(75.47 MHz, DMSO-d6) d 182.3, 172.1, 163.8, 158.5, 152.3,N
OH
NO2
1
N
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4
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Scheme 1 Synthetic rou146.2, 145, 138.2, 138, 137, 136, 134.6, 134, 132, 121.6, 122.1,
120, 117.5, 110.9, 108.1, 35.9; MS (IS) m/z [MH+] 468.7; Anal.
Calcd for C21H14ClN5O6 (%): C, 53.92; N, 14.97. Found: C,
54.10; N, 14.56.
2.6.16. 1-Methyl-6-hydroxy-3-(N3-nephthylureido)carbonyl-4-
oxo-pyrido[2,3-h]quinoline (23)
White solid, yield: 44%, mp > 290 C; FT-IR (KBr) 3412
(OH), 2810 (C–H), 1712 (C‚O), 1672 (Amide-I), 1542
(Amide-II), 1244 (Amide-III) cm1; 1H NMR (300 MHz,
DMSO-d6) d 11.26 (bs, 1H, OH), 10.43 (bs, 1H, NH), 9.64
(bs, 1H, NH), 9.44–8.23 (m, 3H, pyrido ring), 9.18 (s, 1H,
H-2), 8.16 (q, 1H, J= 4.77 Hz, H-5), 7.83–6.72 (m, 7H, naph-
thyl ring), 4.23 (s, 3H, CH3);
13C NMR (75.47 MHz, DMSO-
d6) d 181.5, 174.4, 164.6, 154.2, 156.3, 143.5, 141.2, 138.2,
137.3, 135.2, 129.2, 127.1, 126.4, 125.8, 125.2, 124.5, 123.7,
123.2, 120.6, 118.7, 117.1, 111.2, 109.5, 108.3, 35.4; MS (IS)
m/z [MH+] 441.1; Anal. Calcd for C25H18N4O4 (%): C,
68.49; N, 12.78. Found: C, 68.71; N, 12.98.
2.7. General procedure for the synthesis of piperazinyl carbonyl
pyridoquinolones (24–33)
Compound 6 (1.3 g, 0.005 mol) was dissolved in dry benzene
(15 ml), cooled to 0–5 C in ice-bath and thionyl chlorideN
OH
NH2
2
N
OH
HN
3
COOEt
COOEt
N
OH
N
6
COOH
O
H3C
EMME 110 °C
te of compounds 1–6.
172 N.B. Patel et al.(2 ml) was added drop by drop with stirring; the reaction mix-
ture was protected from humidity with calcium chloride guard
tube and heated for 3–5 h at 60 C on water bath, excess of
thionyl chloride was removed by distillation with benzene to
give pure acid chloride 7, in this anhydrous methanol
(25 ml), pyridine (0.5 ml) and substituted piperazines
(0.005 mol) were added and reﬂuxed for 7–10 h. The reaction
mass was poured into acidic ice-water (50 ml 0.5% HCl).
The product was precipitated, ﬁltered and recrystalized from
ethanol. Similarly other nine derivatives 25–33 have been pre-
pared by the same method.
2.7.1. 1-Methyl-6-hydroxy-3-(4-N-methylpiperazinyl)carbonyl-
4-oxo-pyrido[2,3-h] quinoline (24)
White solid, yield: 70%, mp 202–206 C; FT-IR (KBr) 3345
(OH), 2795 (C–H), 1723 (C‚O), 1676 (Amide-I), 1331 (C–
N), 1280 (Amide-III) cm1; 1H NMR (300 MHz, DMSO-
d6) d 11.14 (bs, 1H, OH), 9.43–8.19 (m, 3H, pyrido ring),
9.12 (s, 1H, H-2), 8.16 (q, 1H, J= 4.71 Hz, H-5), 4.13 (s,
3H, CH3), 3.42–3.19 (m, 4H, piperazine), 2.88–2.72 (m, 4H,
piperazine), 2.28 (s, 3H, CH3);
13C NMR (75.47 MHz,
DMSO-d6) d 184.5, 170.1, 156.4, 150.4, 147.1, 139.2, 137.8,
137.3, 121.6, 121.1, 116.9, 109.5, 108.4, 56.5, 47.2, 42.6,
37.8; MS (IS) m/z [MH+] 353.1; Anal. Calcd for
C19H20N4O3 (%): C, 64.76; N, 15.90. Found: C, 64.22; N,
16.15.N
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Scheme 2 Synthetic rout2.7.2. 1-Methyl-6-hydroxy-3-(4-N-ethylpiperazinyl)carbonyl-4-
oxo-pyrido[2,3-h]quinoline (25)
White solid, yield: 73%, mp 220–223 C; FT-IR (KBr) 3414
(OH), 2794 (C–H), 1719 (C‚O), 1679 (Amide-I), 1335 (C–
N), 1262 (Amide-III) cm1; 1H NMR (300 MHz, DMSO-d6)
d 10.83 (bs, 1H, OH), 9.24–8.13 (m, 3H, pyrido ring), 9.02
(s, 1H, H-2), 8.07 (q, 1H, J= 4.68 Hz, H-5), 4.12 (s, 3H,
CH3), 3.29–3.12 (m, 4H, piperazine), 2.82–2.58 (m, 4H, piper-
azine), 2.35 (q, 2H, J= 7.14 Hz, CH2), 1.47 (t, 3H,
J= 7.14 Hz, CH3);
13C NMR (75.47 MHz, DMSO-d6) d
183.3, 169.5, 155.2, 151.5, 146.5, 138.6, 137.4, 137, 122.6,
120.2, 118.2, 109.2, 107.8, 56.5, 47.2, 36.8, 34.6, 13.3; MS
(IS) m/z [MH+] 367; Anal. Calcd for C20H22N4O3 (%): C,
65.56; N, 15.29. Found: C, 65.21; N, 15.46.
2.7.3. 1-Methyl-6-hydroxy-3-(4-N-hydroxyethylpiperazinyl)-
carbonyl-4-oxo-pyrido[2,3-h]quinoline (26)
White solid, yield: 76%, mp 191–194 C; FT-IR (KBr) 3440
(OH), 2797 (C–H), 1722 (C‚O), 1676 (Amide-I), 1340 (C–
N), 1261 (Amide-III) cm1; 1H NMR (300 MHz, DMSO-d6)
d 10.94 (bs, 1H, OH), 9.33–8.17 (m, 3H, pyrido ring), 9.08
(s, 1H, H-2), 8.03 (q, 1H, J= 4.74 Hz, H-5), 3.49–3.22 (m,
4H, piperazine), 2.92–2.68 (m, 4H, piperazine), 4.12 (s, 3H,
CH3), 3.57 (t, 2H, J= 7.23 Hz, CH2), 2.63 (t, 2H,
J= 7.23 Hz, CH2), 2.39 (bs, 1H, OH);
13C NMR
(75.47 MHz, DMSO-d6) d 183.9, 172.3, 156.2, 150.5, 146.6,N
OH
N
COCl
O
H3C
N
OH
N
CONHCONH
O
H3C
anhyd. CH3OH
23
7
3, 4-CH3, 
O2-5-Cl
H2NCOHN
e of compounds 7–23.
Synthesis and antimicrobial activity of carbonyl pyridoquinolones 173138.8, 137.8, 135.9, 121.6, 120.3, 116.8, 110.5, 108.7, 60.4, 57.8,
54.5, 46.1, 35.9; MS (IS) m/z [MH+] 383; Anal. Calcd for
C20H22N4O4 (%): C, 62.82; N, 14.65. Found: C, 62.96; N,
14.82.
2.7.4. 1-Methyl-6-hydroxy-3-(4-N-phenylpiperazinyl)carbonyl-
4-oxo-pyrido[2,3-h] quinoline (27)
White solid, yield: 73%, mp 252–256 C; FT-IR (KBr) 3430
(OH), 2800 (C–H), 1722 (C‚O), 1674 (Amide-I), 1350 (C–N),
1254 (Amide-III) cm1; 1H NMR (300 MHz, DMSO-d6) d
11.18 (bs, 1H, OH), 9.32–8.24 (m, 3H, pyrido ring), 9.19 (s,
1H, H-2), 8.15 (q, 1H, J= 4.65 Hz, H-5), 7.97–6.95 (m, 5H,
Ar-H), 4.22 (s, 3H, CH3), 3.51–3.28 (m, 4H, piperazine), 2.84–
2.62 (m, 4H, piperazine); 13C NMR (75.47 MHz, DMSO-d6) d
184, 174.5, 156.5, 150.3, 149.6, 145.2, 138, 135.5, 132.8, 129.2,
123.5, 122.8, 118.3, 116.2, 114.7, 112.5, 110.1, 48.4, 42.1, 36.7;
MS (IS) m/z [MH+] 415.2; Anal. Calcd for C24H22N4O3 (%):
C, 69.55; N, 13.52, Found: C, 70.12; N, 13.40.
2.7.5. 1-Methyl-6-hydroxy-3-[4-N-(2,3-dichlorophenyl)
piperazinyl]carbonyl-4-oxo-pyrido [2,3-h]quinoline (28)
Light brown solid, yield: 75%, mp 282–284 C; FT-IR (KBr)
3413 (OH), 2803 (C–H), 1723 (C‚O), 1672 (Amide-I), 1340
(C–N), 1263 (Amide-III) cm1; 1H NMR (300 MHz, DMSO-
d6) d 11.23 (bs, 1H, OH), 9.14–8.03 (m, 3H, pyrido ring),
8.93 (s, 1H, H-2), 7.98 (q, 1H, J= 4.71 Hz, H-5), 7.83–6.69
(m, 3H, Ar-H), 4.01 (s, 3H, CH3), 3.36–3.18 (m, 4H, pipera-N
OH
N
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Scheme 3 Synthetic routezine), 2.88–2.67 (m, 4H, piperazine); 13C NMR (75.47 MHz,
DMSO-d6) d 183.6, 173.2, 156.5, 151.4, 151.1, 147.1, 139.2,
137.4, 136.3, 128.2, 125.3, 123.0, 122.1, 119.8, 118.2, 118.0,
111.2 110.5, 109.2, 48.7, 43.4, 36.3; MS (IS) m/z [MH+]
484.4; Anal. Calcd for C24H20Cl2N4O3 (%): C, 59.64; N,
11.59. Found: C, 59.89; N, 11.40.
2.7.6. 1-Methyl-6-hydroxy-3-[4-N-(2,6-dichlorophenyl)
piperazinyl]carbonyl-4-oxo-pyrido[2,3-h]quinoline (29)
Light brown solid, yield: 75%, mp 272–275 C; FT-IR (KBr)
3433 (OH), 2802 (C–H), 1721 (C‚O), 1660 (Amide-I), 1347
(C–N), 1259 (Amide-III) cm1; 1H NMR (300 MHz, DMSO-
d6) d 11.14 (bs, 1H, OH), 9.23–8.12 (m, 3H, pyrido ring),
9.13 (s, 1H, H-2), 8.07 (q, 1H, J= 4.77 Hz, H-5), 7.85–6.78
(m, 3H, Ar-H), 3.98 (s, 3H, CH3), 3.52–3.23 (m, 4H, pipera-
zine), 2.86–2.75 (m, 4H, piperazine); 13C NMR (75.47 MHz,
DMSO-d6) d 183.3, 172.4, 156.9, 151.4, 150.2, 146.3, 139.2,
138.4, 137.9, 136.1, 127.3, 122.2, 121.0, 120.6, 117.6, 110.3,
108.7, 49.3, 44.1, 36.6; MS (IS) m/z [MH+] 484.1; Anal. Calcd
for C24H20Cl2N4O3 (%): C, 59.64; N, 11.59. Found: C, 59.40;
N, 11.61.
2.7.7. 1-Methyl-6-hydroxy-3-[4-N-(4-methoxyphenyl)
piperazinyl]carbonyl-4-oxo-pyrido [2,3-h]quinoline (30)
White solid, yield: 70%, mp > 290 C; FT-IR (KBr) 3330
(OH), 2791 (C–H), 1719 (C‚O), 1673 (Amide-I), 1341
(C–N), 1257 (Amide-III), 1240, 1032 (C–O–C) cm1; 1HN
OH
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O
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N
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O
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174 N.B. Patel et al.NMR (300 MHz, DMSO-d6) d 11.05 (bs, 1H, OH), 9.24–8.13
(m, 3H, pyrido ring), 8.96 (s, 1H, H-2), 8.11 (q, 1H,
J= 4.80 Hz, H-5), 7.86–6.69 (m, 4H, Ar-H), 3.93 (s, 3H,
CH3), 3.67 (s, 3H, OCH3), 3.36–3.15 (m, 4H, piperazine),
2.91–2.69 (m, 4H, piperazine); 13C NMR (75.47 MHz,
DMSO-d6) d 185.3, 169.3, 155.7, 149.8, 148.1, 147.1, 142.2,
139.0, 137.7, 135.9, 121.3, 120.1, 118.0, 114.4, 113.2, 109.8,
107.8, 57.1, 48.7, 45.1, 36.9; MS (IS) m/z [MH+] 445.2; Anal.
Calcd for C25H24N4O4 (%): C, 67.55; N, 12.60. Found: C,
67.11; N, 12.55.
2.7.8. 1-Methyl-6-hydroxy-3-(3-methylpiperazinyl)carbonyl-4-
oxo-pyrido[2,3-h]quinoline (31)
White solid, yield: 67%, mp 211–214 C; FT-IR (KBr) 3433
(OH), 2794 (C–H), 1717 (C‚O), 1670 (Amide-I), 1342
(C–N), 1259 (Amide-III) cm1; 1H NMR (300 MHz, DMSO-
d6) d 11.25 (bs, 1H, OH), 9.22–8.18 (m, 3H, pyrido ring),
8.92 (s, 1H, H-2), 8.15 (q, 1H, J= 4.74 Hz, H-5), 4.02 (s,
3H, CH3), 3.29–3.21 (m, 4H, piperazine), 2.96–2.87 (m, 1H,
piperazine), 2.64–2.56 (m, 2H, piperazine), 2.23 (bs, 1H,Table 1 Antibacterial assay of compounds 1–33 against gram posi
Compound R B. subtilis
ATCC 6633
Potency (%) B. subtilis
ATCC 6633
P
Ciproﬂoxacin Gatiﬂoxacin
UH UL SH SL UH UL SH SL
1 – – – 25 13 – – – 29 15 –
2 – – – 26 14 – – – 28 15 –
3 – – – 24 13 – – – 32 17 –
4 – 6 – 26 15 – 5 – 30 16 –
5 – 7 – 27 15 – – – 31 17 –
6 – 13 8 25 14 32.2 14 8 30 18 2
8 H 14 08 25 15 45.9 18 08 36 23 3
9 2-Cl 16 08 28 16 50.0 18 09 33 21 4
10 3-Cl 18 07 32 20 41.7 14 09 35 22 2
11 4-Cl 14 06 24 14 50.0 16 10 30 19 3
12 2-OCH3 17 08 28 17 50.0 16 10 28 19 3
13 4-OCH3 15 10 25 16 50.0 16 10 33 21 3
14 2-CH3 15 11 29 19 33.7 10 07 32 18 2
15 3-CH3 13 08 28 17 35.4 14 10 34 20 3
16 4-CH3 12 06 24 14 38.6 12 09 28 17 3
17 2-NO2 13 07 23 12 54.3 17 08 32 19 4
18 3-NO2 17 08 28 14 50.0 18 10 35 22 3
19 4-NO2 14 08 28 15 46.5 15 08 30 19 3
20 2,5-(Cl)2 14 08 27 16 42.5 15 07 26 18 3
21 2-Cl-5-NO2 13 08 29 16 39.7 14 10 32 20 2
22 2-NO2-5-Cl 14 07 30 17 40.6 13 08 33 19 3
23 – 12 07 25 13 46.1 14 08 35 19 3
24 4-CH3 26 17 30 19 81.2 25 17 36 20 6
25 4-CH2CH3 29 14 32 21 81.0 23 16 30 19 6
26 4-CH2CH2OH 23 12 26 14 86.0 20 13 26 17 6
27 4-C6H5 25 13 29 16 82.4 22 14 28 17 7
28 4-2,3-(Cl)2-C6H3 26 13 31 16 82.0 25 17 32 21 6
29 4-2,6-(Cl)2-C6H3 22 13 26 15 81.2 28 17 36 22 6
30 4-4-OCH3-C6H4 21 13 28 15 84.1 27 19 33 23 6
31 3-CH3 26 17 29 19 83.3 26 17 34 21 7
32 3,5-(CH3)2 20 12 25 14 77.5 22 14 30 18 6
33 – 20 13 30 18 57.9 20 13 33 19 5
SH = zone of inhibition of standard at concentration 100 lg/ml; SL = z
UH = zone of inhibition of compound at concentration 100 lg/ml; UL =NH), 1.37 (d, 3H, CH3);
13C NMR (75.47 MHz, DMSO-d6)
d 183.4, 169.8, 156.2, 150.8, 147.3, 138.2, 137.8, 136.2, 121.7,
120.2, 117.3, 110.6, 110.1, 54.7, 53.5, 51.1, 50.7, 35.8, 19.7;
MS (IS) m/z [MH+] 353.5; Anal. Calcd for C19H20N4O3
(%): C, 64.76; N, 15.90. Found: C, 64.22; N, 15.96.
2.7.9. 1-Methyl-6-hydroxy-3-(3,5-dimethylpiperazinyl)-
carbonyl-4-oxo-pyrido[2,3-h] quinoline (32)
White solid, yield: 71%, mp 190–194 C; FT-IR (KBr) 3441
(OH), 2789 (C–H), 1714 (C‚O), 1669 (Amide-I), 1332 (C–
N), 1256 (Amide-III) cm1; 1H NMR (300 MHz, DMSO-d6)
d 11.13 (bs, 1H, OH), 9.12–8.14 (m, 3H, pyrido ring), 8.89
(s, 1H, H-2), 8.09 (q, 1H, J= 4.65 Hz, H-5), 4.05 (s, 3H,
CH3), 3.23–2.96 (m, 4H, piperazine), 2.81–2.68 (m, 2H, piper-
azine), 2.17 (bs, 1H, NH), 1.19 (d, 2 · 3H, CH3); 13C NMR
(75.47 MHz, DMSO-d6) d 184.6, 169.4, 156.5, 152.0, 147.8,
138.0, 137.8, 136.9, 121.1, 120.8, 118.3, 110.0, 108.1, 54.3,
52.6, 51.5, 49.9, 36.3, 19.4, 16.8; MS (IS) m/z [MH+] 367.8;
Anal. Calcd for C20H22N4O3 (%): C, 65.56; N, 15.29. Found:
C, 65.95; N, 15.20.tive bacteria.
otency (%) S. aureus
ATCC 9144
Potency (%) S. aureus
ATCC 9144
Potency (%)
Ciproﬂoxacin Gatiﬂoxacin
UH UL SH SL UH UL SH SL
– – 26 13 – – – 31 15 –
– – 27 14 – – – 30 16 –
– – 25 13 – – – 32 18 –
– – 26 13 – – – 29 16 –
7 – 27 14 – 5 – 30 17 –
2.4 13 7 26 15 26.3 13 8 31 18 22.5
6.9 16 10 28 18 42.0 14 09 34 20 32.3
1.0 17 09 29 18 46.5 13 09 32 18 34.0
7.0 16 08 27 17 46.3 13 08 30 18 33.3
9.0 15 10 28 18 37.9 12 7 33 20 27.0
9.2 15 10 30 17 42.9 14 07 30 18 37.3
9.2 15 09 30 18 40.1 12 06 28 16 36.7
6.0 15 10 32 18 38.6 12 07 32 18 35.6
1.5 13 09 28 16 39.6 13 08 34 18 35.9
0.5 13 09 26 15 39.0 12 06 28 17 33.3
4.1 14 10 29 18 54.8 14 08 26 16 42.0
8.4 17 10 30 17 50.0 14 08 28 17 39.2
6.7 17 08 28 18 46.5 13 08 34 18 35.9
8.5 16 07 25 15 53.8 14 08 30 18 36.7
9.7 17 07 32 15 39.2 12 06 30 17 34.7
2.3 15 07 26 14 53.6 14 08 28 17 39.2
6.5 15 07 30 16 47.0 14 08 32 17 41.0
6.7 28 18 32 20 82.8 26 14 33 19 72.6
8.0 27 16 28 18 96.8 23 13 26 15 84.8
4.9 23 14 26 16 83.3 22 11 28 16 71.8
2.0 27 15 30 19 81.0 26 14 32 20 70.7
6.9 22 17 27 18 74.3 23 12 32 18 66.0
9.7 28 18 32 20 82.8 21 12 27 16 70.7
8.0 25 15 26 15 96.8 24 16 27 18 81.6
0.7 25 15 30 16 84.1 26 16 35 20 69.7
6.0 26 15 33 16 82.0 27 16 36 20 72.5
3.4 22 13 30 17 68.5 22 13 32 18 63.6
one of inhibition of standard at concentration 50 lg/ml.
zone of inhibition of compound at concentration 50 lg/ml.
Synthesis and antimicrobial activity of carbonyl pyridoquinolones 1752.7.10. 1-Methyl-6-hydroxy-3-(4-N-methylpiperazinyl)-
aminocarbonyl-4-oxo-pyrido[2,3-h]quinoline (33)
White solid, yield: 70%, mp 262–264 C; FT-IR (KBr) 3319
(OH), 2795 (C–H), 1717 (C‚O), 1675 (Amide-I), 1335 (C–N),
1262 (Amide-III) cm1; 1H NMR (300 MHz, DMSO-d6) d
11.06 (bs, 1H, OH), 10.54 (bs, 1H, NH), 9.33–8.12 (m, 3H, pyr-
ido ring), 9.14 (s, 1H, H-2), 8.04 (q, 1H, J= 4.68 Hz, H-5), 4.12
(s, 3H, CH3), 3.22–3.02 (m, 4H, piperazine), 2.83–2.71 (m, 4H,
piperazine), 2.29 (s, 3H, CH3);
13C NMR (75.47 MHz,
DMSO-d6) d 185.0, 163.4, 156.1, 150.2, 147.1, 138.1, 137.5,
136.9, 122.3, 120.8, 118.5, 110.2, 107.5, 56.3, 47.2, 40.6, 36.2;
MS (IS) m/z [MH+] 368.5; Anal. Calcd for C19H21N5O3 (%):
C, 62.11; N, 19.06. Found: C, 62.25; N, 18.90.
2.8. Antimicrobial activity (Dubois and St-Pierre, 2000;
Microbial Assay of Antibiotic, 2004; Hong et al., 1997)
The in vitro antimicrobial activities of compounds 1–33 were
carried out by diffusion method, and were screened against
two gram positive bacteria (Bacillus subtilis ATCC 6633 and
Staphylococcus aureus ATCC 9144) and two gram negative
bacteria (Escherichia coli ATCC 25922 and Pseudomonas aeru-Table 2 Antibacterial assay of compounds 1–33 against gram nega
Compound R E. coli ATCC
25922
Potency (%) E. col ATCC
25922
P
Ciproﬂoxacin Gatiﬂoxacin
UH UL SH SL UH UL SH SL
1 – – – 24 12 – – – 29 15 –
2 – – – 25 13 – – – 30 16 –
3 – – – 26 13 – – – 29 15 –
4 – 7 – 24 12 – 6 – 28 14 –
5 – 6 – 25 12 – 5 – 29 14 –
6 – 12 9 24 13 36.5 13 10 29 17 2
8 H 14 09 26 15 45.6 13 06 32 21 2
9 2-Cl 14 10 28 18 55.2 11 06 26 16 3
10 3-Cl 17 09 30 18 46.7 14 07 29 20 2
11 4-Cl 16 09 25 17 45.6 13 07 25 16 3
12 2-OCH3 14 08 24 16 41.0 10 07 27 17 2
13 4-OCH3 13 07 24 14 45.9 14 08 30 20 2
14 2-CH3 16 08 27 16 50.0 15 08 35 22 3
15 3-CH3 16 09 29 18 42.9 12 06 30 20 2
16 4-CH3 13 07 24 14 45.9 10 06 28 18 3
17 2-NO2 16 07 26 15 53.6 13 06 27 16 2
18 3-NO2 13 06 22 13 50.0 14 08 32 20 3
19 4-NO2 13 08 24 15 41.0 12 07 30 19 2
20 2,5-(Cl)2 11 06 22 12 45.6 10 06 28 17 2
21 2-Cl-5-NO2 14 08 28 16 42.9 13 07 30 19 3
22 2-NO2-5-Cl 16 09 26 17 50.0 14 08 32 20 3
23 – 14 08 24 15 45.6 13 08 30 19 2
24 4-CH3 25 17 29 19 79.4 24 16 34 20 6
25 4-CH2CH3 23 14 24 16 88.5 22 15 27 15 6
26 4-CH2CH2OH 20 12 22 14 84.1 21 15 33 17 6
27 4-C6H5 24 14 25 16 90.6 24 15 30 18 7
28 4-2,3-(Cl)2-C6H3 25 16 28 19 79.4 23 15 30 19 6
29 4-2,6-(Cl)2-C6H3 26 15 29 19 79.4 22 13 30 17 6
30 4-4-OCH3-C6H4 25 14 26 17 87.1 25 14 34 21 6
31 3-CH3 25 13 28 15 87.1 25 13 32 21 6
32 3,5-(CH3)2 21 13 24 16 77.1 25 17 34 22 6
33 – 20 14 27 19 55.2 22 14 34 22 4
SH = zone of inhibition of standard at concentration 100 lg/ml; SL = zo
UH = zone of inhibition of compound at concentration 100 lg/ml; UL =ginosa ATCC 9027). The antifungal activity was screened
against fungal species Candida albicans ATCC 10231, by
measuring the zone of inhibition on agar plates at two different
concentrations 100 and 50 lg/ml. Ciproﬂoxacin and gatiﬂoxa-
cin were used as standard antibacterial drugs and ﬂuconazole
was used as a standard antifungal drug.
3. Results and discussion
3.1. Chemistry
Synthetic routes for carbonyl pyridoquinolones 8–33 are
shown in Schemes 2 and 3. The required 1-methyl-6-hydro-
xy-4-oxo-pyrido[2,3-h]quinoline-3-carboxylic acid 6 was syn-
thesized according to described process in Scheme 1.
Nitroxoline 1 was easily reduced to 5-amino-8-hydroxy quin-
oline 2 with SnCl2ÆHCl (Lee and Chang, 1994; Patel and
Chauhan, 2005). The synthesis of acid 6 was achieved from
compound 2 by multistep process (Lee and Chang, 1996;
Lee et al., 1992; Reitseona, 1948). Compound 2 on reaction
with diethyl ethoxy methylene malonate yielded diethyl
N-(8-hydroxy-5-quinolinyl)amino ethylenemalonate 3. Thetive bacteria.
otency (%) P. aeruginosa
ATCC 9027
Potency (%) P. aeruginosa
ATCC 9027
Potency (%)
Ciproﬂoxacin Gatiﬂoxacin
UH UL SH SL UH UL SH SL
– – 27 14 – – – 29 16 –
– – 28 14 – – – 30 17 –
– – 27 13 – – – 31 16 –
– – 28 15 – – – 30 16 –
6 – 29 15 – 7 – 32 18 –
6.5 12 9 28 16 26.5 12 8 32 18 22.6
7.0 16 08 28 15 53.4 14 07 28 18 36.1
1.5 15 07 25 15 50.0 17 08 32 21 37.9
7.0 16 07 28 14 56.4 17 09 32 20 40.6
5.4 15 08 22 14 54.8 15 08 32 20 34.7
3.7 14 06 22 13 54.3 16 09 35 21 35.9
9.7 18 09 28 18 50.0 17 07 34 22 36.5
0.8 18 08 30 18 50.0 15 09 30 20 39.3
5.0 16 07 24 15 54.0 18 08 36 22 32.4
3.3 16 07 25 15 53.8 34 08 30 20 29.7
8.7 18 10 30 20 42.9 13 06 26 19 27.6
1.5 17 09 28 18 46.3 15 09 34 21 32.3
7.3 18 09 30 21 39.7 12 07 36 20 29.5
9.7 17 08 25 15 57.8 16 08 27 18 42.4
0.7 18 09 29 20 42.9 17 08 32 20 41.0
1.5 17 09 28 18 46.3 15 09 32 20 34.0
9.7 13 08 29 16 50.0 16 09 33 21 34.7
4.3 26 17 30 19 81.2 24 13 30 20 65.1
8.8 25 17 28 20 77.1 28 16 35 24 63.6
4.3 24 17 28 19 77.1 22 13 28 19 63.0
4.3 22 14 25 15 85.7 24 13 32 19 66.7
6.9 19 12 22 12 88.5 20 12 27 15 70.7
8.5 21 12 23 13 89.6 23 12 29 16 74.9
5.3 25 20 28 20 85.2 25 14 32 20 65.1
3.6 26 20 30 20 84.1 27 20 35 24 63.0
0.0 22 13 24 13 93.1 25 15 30 20 70.7
6.3 25 15 30 19 74.3 25 17 34 22 61.6
ne of inhibition of standard at concentration 50 lg/ml.
zone of inhibition of compound at concentration 50 lg/ml.
176 N.B. Patel et al.1H NMR spectrum of compound 3 showed doublet at d
11.76 ppm and d 8.57 ppm equivalent to one proton of NH
and CH respectively with coupling value J= 12.81 Hz. The
cyclization of compound 3 in presence of diphenyl ether at
200 C produced ethyl 6-hydroxy-4-oxo-pyrido[2,3-h]quino-
line-3-carboxylate 4. The IR spectra of compound 4 showed
strong C‚O stretching at 1707 cm1. The N-methylation of
compound 4 with methyl iodide afforded compound 5 which
showed singlet equivalent to three protons of methyl group at
d 4.08 ppm in 1H NMR spectrum. The acid catalyzed hydro-
lysis of compound 5 yielded acid 6. The formation of this
compound was conﬁrmed by 1H NMR spectrum which
showed broad signal at d 14.97 ppm equivalent to one proton
of COOH group. Acid chloride 7 was obtained from acid 6
by treatment with thionyl chloride, which on condensation
reaction with substituted aryl ureas and substituted pipera-
zines produced desired compounds 8–33. All the carbonyl
pyridoquinolones 8–33 showed satisfactory IR as well as
NMR spectral results and for all the compounds satisfactory
elemental analyses were obtained.
3.2. Antimicrobial activity
The results of antibacterial activity are summarized in Tables 1
and 2. Ureido carbonyl derivative of pyridiquinolone contain-
ing 2-nitro group (compound 17) showed highest activities
against both gram positive bacteria B. subtilis and S. aureus;
i.e. 54.3% potency compared to ciproﬂoxacin and 44.1% po-
tency compared to gatiﬂoxacin against B. subtilis, and 54.8%
potency compared to ciproﬂoxacin and 42.0% potency com-
pared to gatiﬂoxacin against S. aureus. Whereas 2,5-dichloro
group containing compound (compound 20) exhibited greater
activity against gram negative bacteria P. aeruginosa; i.e.
57.8% potency compared to ciproﬂoxacin and 42.4%
compared to gatiﬂoxacin while compound 17 (R = 2-NO2)
showed good activity with 53.6% potency compared to cipro-
ﬂoxacin against gram negative bacteria E. coli. The nitro deriv-
atives of ureido carbonyl pyridiquinolones exhibited decrease
activity against P. aeruginosa. The decreased activity of ureido
carbonyl pyridiquinolone was observed against E. coli while it
containing 2-methoxy group. Compounds 9–11, 18, 19, 21 and
23 showed poor activities while the remaining compounds 8,
12–17, 20, 22 and 23 of this series were found inactive against
fungi C. albicans in comparison to ﬂuconazole. Carbonyl pyr-
idoquinolone containing 1-amino-4-methyl piperazine (com-
pound 33) did not show good activity while ethyl, phenyl
and 4-methoxy phenyl piperazine derivatives exhibited better
activities against gram positive bacteria. Carbonyl pyridoqui-
nolone containing phenyl piperazine (compound 27) showed
very good activity against E. coli; 90.6% potency as compared
to ciproﬂoxacin and 74.3% potency as compared to gatiﬂoxa-
cin. Compound 32 (R = 3,5-(CH3)2) exhibited highest activity
i.e. 93.1% potency against P. aeruginosa compared to cipro-
ﬂoxacin. Compounds 24, 27 and 29 displayed poor activities
while the remaining compounds 25, 26, 28, 30–33 of this serieswere found inactive against fungi C. albicans as compared to
ﬂuconazole. Screening results revels that the piperazine con-
taining compounds of carbonyl pyridiquinolone enhanced
the activity of parent compound pyridiquinolone 6 against
both gram positive and gram negative bacteria. Most of the
piperazine derivatives of parent compound gave more than
70% potency against bacteria as compared to ciproﬂoxacin
and above 60% as compared to gatiﬂoxacin. Most of the com-
pounds showed poor activity against fungi C. albicans. Piper-
azinyl carbonyl pyridoquinolones showed better antibacterial
activity than that of ureido carbonyl pyridoquinolones.Acknowledgements
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